CORE--ADHERENCE CORE

坚持核心是一个共享的资源，支持三个干预 行为成分的研究。 Shrw资源的目标是： 1)促进受试者对纤维、吡罗昔康和DFMO的依从性 试验，2）咨询并提供适用于 其他核心，3）记录健康行为特征的敏感性 区分好的、边缘的和差的粘附者， 4）确定与短期和长期相关的因素 坚持成功和失败的三个代表性的癌症预防 和对照试验，参与者有患结肠癌的风险， IV期试验中依从性低的潜在诱发因素，5） 确定基于健康行为特征的依从性的有效性 干预 纤维（n 1000）、吡罗昔康（n=100）和DFMO中的受试者 （n=100）试验对象为40-80岁有腺瘤性息肉病史的奥尔兹。 使用了原始相关数据。 此外，一个前瞻性的病例对照 与良好匹配的不良和边缘粘附者的子样本策略 粘附者对照（n=81）用于评估目标#4。 描述性统计， 针对目标#4的Harvey-Goldstein ML-2分析和基于经济的效率 将对目标#5进行分析。 核心结果包括依从性 促进，基于健康行为概况的效率估计 干预，测试一般和个性化的有效性， 干预措施，并描述在依从性失败的因素， 第四阶段癌症预防和控制社区为基础的准备 结肠癌高危人群的临床试验

Adherence Core is a shared resource which supports the three intervention studies with behavioral components. The aims of the shred resource are: 1) Promote participant adherence/compliance with fiber, piroxicam and DFMO trials, 2) Consult with and provide behavioral findings applicable to other Cores, 3) document the Health Behavior Profile for sensitivity in distinguishing among good, marginal and poor adherers, making necessary refinements, and 4) Identify factors associated with short and long-term adherence success and failure in the three representative cancer prevention and control trials with participants at risk for colon cancer, to identify potential predisposing factors for low adherence in Phase IV trials, 5) Identify the efficacy of the Health Behavior Profile-based adherence intervention. Subjects in the fiber (n 1000), piroxicam (n=100) and DFMO (n=100) trials are 40-80 year olds with a history of adenomatous polyps. Primarily correlational data are used. Also, a prospective case control strategy with a subsample of poor and marginal adherers matched with good adherer controls (n=81) is used to assess aim #4. Descriptive statistics, Harvey-Goldstein ML-2 analysis for aim #4 and an economic-based efficiency analysis for aim #5 will be performed. Core outcomes include adherence promotion, an efficiency estimate of the Health Behavior Profile-based intervention, a test of the effectiveness of the general and individualized interventions, and description of factors in adherence failure in preparation for Phase IV cancer prevention and control community-based trials with people at risk for colon cancer.